摘要
目的观察低强度华法令抗凝治疗高卒中风险、高出血风险心房纤颤患者的抗栓疗效和安全性。方法选取CHADS2卒中危险评分3～6分、HEMORR2HAGES评分≥2分的心房纤颤患者60例,随机分成两组:每组各30例。一组为低强度华法令治疗组〔1.5≤国际标准化比值(INR)≤2.0〕;另一组为阿司匹林对照组。观察各组卒中和出血事件的发生率。结果治疗组的血栓发生率明显低于对照组,出血发生率和对照组无显著差异。结论对于高卒中风险、高出血风险的心房纤颤患者,低强度华法令抗凝能有效减少血栓事件发生,使用安全可靠。
Objective To observe the effect and satety of low intensity warfarin in the therapy for patients with artrial fibrillation who with high risk of thrombo-embolism and hemorrhagic.Methods 60 patients with artrial fibrillation who CHADS2 score 3-6 and HEMORR2HAGES score≥2 were randomly divided into two groups.Each group involved 30 cases.The first group was low intensity warfarin group（1.5≤INR≤2.0）.The other was Aspilin group.The incidence of the thrombo-embolism and hemorrhagic was compared.Results The thrombo-embolism events in low intensity warfarin group were lower than in aspilin group（P=0.0336）.The hemorrhagic events in two groups was no statistically significance.There were no serious bleeding in two groups.Conclusion The results suggested that low intensity warfarin might safely and remarkly reduce the incidences of thrombo-embolism events in the therapy for patients with artrial fibrillation who with high risk of thrombo-embolism and hemorrhagic.
出处
《实用心脑肺血管病杂志》
2011年第7期1104-1105,共2页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
关键词
华法令
国际化标准比值
心房纤颤
Warfarin
International standard ratio
Artrial fibrillation
